オンターナル・セラピューティクス | 10-Q：四半期報告書

SEC11/07 05:32

Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"

Benzinga10/30 03:17

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Yahoo Finance10/22 21:00

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga10/15 20:08

Oncternal Therapeutics Cut to Market Perform From Outperform by Northland Capital Markets

Dow Jones09/13 03:59

Oncternal Therapeutics Price Target Announced at $2.00/Share by Northland Capital Markets

Dow Jones09/13 03:59